Latest Results from Immunotherapy Clinical Trials in Triple Negative Breast Cancer

Abstract

Cancer immunotherapy has evolved enormously in the recent years with better understanding of immune reactions, immune microenvironment
and immunosurveillance. Breast cancer is characterized by large heterogeneity, a fact which rather complicated
the development and the approval of novel therapeutic options in comparison to the majority of other solid tumors since each
subtype has required a unique scientific approach and different targets and goals. Triple negative breast cancer (TNBC) is considered
the most aggressive of the breast cancer subtypes with limited treatment options and worse outcome compared to others.
This article summarizes some of the early clinical studies and the recently presented phase III clinical study of immunotherapy
checkpoint inhibitors in this difficult setting.